In patients with type 2 diabetes, pioglitazone, glucagon-like peptide-1 receptor agonists, and sodium glucose cotransporter 2 inhibitors are recommended to improve liver fibrosis [34]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.